December 13, 2021 08:55 US Eastern Time | Source: electroCore, Inc. electroCore, Inc.
Rockaway, New Jersey, U.S.
Rockaway, New Jersey, December 13, 2021 (Global News Service)--electroCore, Inc. (the "Company") (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced the United States The Patent and Trademark Office (USPTO) has issued US Patent No. 11,191,953 to the company concerning the treatment of stroke symptoms.
The newly issued patent relates to a method for the treatment of acute symptoms of stroke or transient ischemic attack (TIA), which is a temporary symptom similar to stroke symptoms, based on the application of transdermal, non-invasive electrical pulses or stimulation.
This newly granted patent belongs to the company and strengthens development work related to trials initiated by certain researchers in the field of stroke, which is the second leading cause of death and the third leading cause of disability in the world. Earlier this year, the company announced the full registration of the TR-VENUS study of non-invasive vagus nerve stimulation (nVNS) for the treatment of acute stroke. "We are pleased with the release of the latest patent, which involves another potentially important use of electroCore's non-invasive method for the treatment of patients with vagus nerve stimulation that has a devastating impact on people's lives," the company's founder and board of directors Member and investor JP Errico commented. Company, he is also the co-inventor of the new patent. "Every year, approximately 15 million people worldwide have a stroke, and our non-invasive vagus nerve stimulator technology may be an effective acute treatment method that can reduce the destructive effects on the brains of these patients. As the researchers initiated stroke trials We are looking forward to understanding the potential role of nVNS in the treatment paradigm of stroke patients worldwide." About electroCore, Inc. ElectroCore, Inc. is a commercial-stage bioelectronics company dedicated to non-invasive vagus nerves. The stimulation treatment platform improves the treatment effect of patients, initially focusing on the treatment of a variety of neurological diseases. The company’s current indications are preventive treatment of cluster headache and migraine, acute treatment of migraine and paroxysmal cluster headache, acute and preventive treatment of adolescent migraine, and adult paroxysmal migraine and persistent migraine. .
For more information, please visit www.electrocore.com.
About gammaCoreTM gammaCoreTM (nVNS) is the first non-invasive hand-held medical treatment applied to the neck. As an adjunct therapy, it treats migraines and cluster headaches by gentle electrical stimulation of the vagus nerve that passes through the skin. As a portable, easy-to-use technology, gammaCore can be self-administered by patients as needed without the potential side effects associated with commonly used drugs. When placed above the vagus nerve in the patient's neck, gammaCore stimulates the afferent fibers of the nerve, which may reduce the patient's pain.
gammaCore (nVNS) is approved by the FDA in the United States and can be used for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with paroxysmal cluster headache in adult patients, and the acute and preventive treatment of adolescent migraine. 12 years and older) and adult patients, as well as paroxysmal migraine and continuous migraine in adult patients. gammaCore obtained the CE mark in the European Union for the acute and/or preventive treatment of adult primary headaches (migraine, cluster headache, trigeminal autonomic headache and continuous migraine) and drug overuse headache.
gammaCore is contraindicated in the following patients:
The safety and effectiveness of gammaCore have not been evaluated in the following patients:
Before using or prescribing this product, please refer to the gammaCore instructions for use for all important warnings and precautions.
Forward-looking statements This press release and other written and oral statements made by electroCore representatives may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore's business prospects and clinical and product development plans; its technology pipeline or potential market; the timing, results and impact of regulatory, clinical and commercial development; the issuance of US and international patents , Expand the scope of intellectual property coverage; the possibility of future business models and sources of income comes from the company's potential to use nVNS to treat symptoms related to acute stroke or TIA, the potential of nVNS in general, especially gammaCore, and other non-historical statements, especially These are statements that use terms, such as "expects", "will", "expects", "believes", "intends", other words with similar meanings, derivatives of these words, and the use of future dates. Due to a variety of factors, actual results may differ from the results predicted in any forward-looking statement. Such factors include (among other things) the ability to raise additional funds to continue the implementation of ElectroCore’s business and product development plans, the inherent uncertainty associated with the development of new products or technologies, the ability to commercialize gammaCore™, potential impact and impact on COVID -19 Regarding electroCore's business, electroCore's operating performance and financial performance, as well as any measures electroCore has and may take in response to COVID-19, any expectations electroCore may have on this, the competition in the industry in which electroCore operates, and the overall market conditions. Any forward-looking statements are made on the date of this press release, and electroCore assumes no obligation to update forward-looking statements or to update the reasons why actual results may differ from the results predicted in forward-looking statements, unless required by law. Investors should review all the information listed here, and should also refer to the risk factor disclosures specified in the reports and other documents submitted by electroCore to the US Securities and Exchange Commission, which can be obtained from www.sec.gov.